Successes and limitations of targeted therapies in renal cell carcinoma.

Détails

ID Serval
serval:BIB_502F2CD856F8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Successes and limitations of targeted therapies in renal cell carcinoma.
Périodique
Progress in tumor research
Auteur⸱e⸱s
Pracht M., Berthold D.
ISSN
2296-1887 (Electronic)
ISSN-L
2296-1887
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
41
Pages
98-112
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Publication types: Journal Article ; Review

Résumé
Until recently, the standard treatment for metastatic renal cell carcinoma (RCC) was nonspecific immunotherapy based on interleukin-2 or interferon-α. This was associated with a modest survival benefit and with significant clinical toxicities. The understanding of numerous molecular pathways in RCC, including HIF, VEGF, mTOR, and the consecutive use of targeted therapies since the beginning of 2005 have significantly improved outcomes for patients with metastatic RCC with an overall survival greater than 2 years. At present, at least 7 targeted agents are approved for first and consecutive lines of treatment of clear cell metastatic RCC. Long-term benefit and extended survival may be achieved through the optimal use of targeted therapies: optimal dosing, adverse event management and treatment duration and compliance. Advances in the finding of prognostic factors highlight the potential for personalizing treatment for patients with metastatic RCC. Data regarding the best sequencing of targeted therapies, predictive biomarkers, best timing of surgery, patient risk profiles, understanding of resistance mechanisms and safety of targeted therapies are growing and will provide a further step ahead in the management of advanced RCC. In parallel, a new class of therapeutics is emerging in RCC: immunotherapy; in particular check-point blockade antibodies are showing very promising results.

Mots-clé
Antineoplastic Agents/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/genetics, Humans, Immunotherapy/methods, Kidney Neoplasms/drug therapy, Kidney Neoplasms/genetics, Molecular Targeted Therapy/methods, Molecular Targeted Therapy/trends
Pubmed
Création de la notice
07/02/2015 14:01
Dernière modification de la notice
20/08/2019 14:06
Données d'usage